Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
65.70
-1.00 (-1.50%)
Mar 31, 2025, 1:34 PM EDT - Market open

Belite Bio Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
10.066.823.952.382.06
Research & Development
29.9424.848.877.423.69
Operating Expenses
4031.6712.829.85.74
Operating Income
-40-31.67-12.82-9.8-5.74
Interest Expense
-0.02-0.03-0.02--0.02
Interest & Investment Income
3.740.070.020.010.01
Currency Exchange Gain (Loss)
0.14-00.17--
Other Non Operating Income (Expenses)
---0.13-
Pretax Income
-36.14-31.62-12.65-9.67-5.75
Income Tax Expense
0.010.01--0
Net Income
-36.14-31.63-12.65-9.67-5.75
Net Income to Common
-36.14-31.63-12.65-9.67-5.75
Shares Outstanding (Basic)
312720109
Shares Outstanding (Diluted)
312720109
Shares Change (YoY)
14.83%33.12%108.74%8.87%-
EPS (Basic)
-1.18-1.19-0.63-1.01-0.65
EPS (Diluted)
-1.18-1.19-0.63-1.01-0.65
Free Cash Flow
-29.35-29.9-11.85-7.55-4.46
Free Cash Flow Per Share
-0.96-1.12-0.59-0.79-0.51
EBITDA
-39.83-31.53-12.76-9.77-5.73
D&A For EBITDA
0.170.140.060.030.02
EBIT
-40-31.67-12.82-9.8-5.74
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q